

Abstract No. : A498

Theme : Anemia, Metabolism, Phosphate Control and Parathyroid Hormone

Anaemia status in patients on PD in the French Peritoneal Dialysis Registry (RDPLF)

Verger, C.¹, Fabre, E.¹, Ryckelynck, J.P.², Azar, R.³, Genestier, S.⁴, Aguilera, D.⁵, Durand, P.Y.⁶, Landru, I.⁷, Attaf, D.⁸, Veniez, G.¹; CH R Dubos, Pontoise¹, CHU Cl?menceau, Caen², CHG, Dunkerque³, hopital Louis Pasteur, Colmar⁴, CH, Vichy⁵, ALTIR, Nancy⁶, CH, Lisieux⁷, CH, Nevers⁸, France

RDPLF has data from France and 6 other countries. The data base is divided into different interconnected modules, one main module which represents 85 % of French PD patients, and optional modules, among them one dealing with anaemia. This study presents the anemia status of French PD patients. Methods : 441 patients, from 22 centers, were included. Centers must send all parameters involved in erythropoiesis such as Hb, CRP, type and doses of erythropoietin (EPO), iron supplementations, vitamin status, etc.. Results : 66 % of PD patients are treated by EPO (40,8 % on Darbepoetin and 59,2 % on Epoetin beta). The average haemoglobin is 12 g/100ml, with no difference between APD and CAPD. 72 % have an haemoglobin concentration higher than 11g. On Darbepoietin 52 % had 1 injection every 2 weeks or more , 17 % on Epoetin beta. 18 % of PD patients had either ferritin<100 µg/l and/or iron saturation < 20 % . Discussion : less frequent use of EPO in PD patients compared to HD is well known. Less frequent doses with Darbepoietin is due to the molecule structure but still 17 % of patients successfully use 1 injection every 2 weeks or more with epoietin beta. Iron deficiency in some patients may be explained by poor digestive absorption and interactions with other medications or food and reluctance to use the intravenous route for iron supplementation Conclusion : data from the RDPLF indicate that 72 % of PD patients in France meet the recommandations for haemoglobin, but 18 % have some degree of iron deficiency. Only 11 % have more than one dose per week. However the use of molecules with different durations of activity may be useful to a precise adjustment of doses at the beginning.